Supernus Pharmaceuticals (SUPN) Presripctions Rising with Back to School - Jefferies
Tweet Send to a Friend
Jefferies analyst David Steinberg reiterated a Buy rating and $40.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN) after Qelbree Rx's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
